Literature DB >> 25267897

Pharmacological interventions for schizotypal personality disorder.

Saeed Farooq1, Birgit A Völlm2, Nusrat Husain3, Nick Huband2, Jutta Stoffers4, Simon Gibbon5, Conor Duggan2, Michael Ferriter6, Klaus Lieb7.   

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: To evaluate the effects of pharmacological interventions for people with Schizotypal Personality Disorder (SzPD).

Entities:  

Year:  2011        PMID： 25267897      PMCID： PMC4176635          DOI： 10.1002/14651858.CD009047

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN： 1361-6137


  22 in total

1.  Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk.

Authors:  Anthony P Morrison; Paul French; Sophie Parker; Morwenna Roberts; Helen Stevens; Richard P Bentall; Shôn W Lewis
Journal:  Schizophr Bull       Date:  2006-09-14       Impact factor: 9.306

2.  The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance.

Authors:  J Endicott; R L Spitzer; J L Fleiss; J Cohen
Journal:  Arch Gen Psychiatry       Date:  1976-06

3.  Functional impairment in patients with schizotypal, borderline, avoidant, or obsessive-compulsive personality disorder.

Authors:  Andrew E Skodol; John G Gunderson; Thomas H McGlashan; Ingrid R Dyck; Robert L Stout; Donna S Bender; Carlos M Grilo; M Tracie Shea; Mary C Zanarini; Leslie C Morey; Charles A Sanislow; John M Oldham
Journal:  Am J Psychiatry       Date:  2002-02       Impact factor: 18.112

4.  Algorithms for pharmacological treatment of personality dimensions: symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioral dysregulation.

Authors:  P H Soloff
Journal:  Bull Menninger Clin       Date:  1998

5.  The Social Functioning Questionnaire: a rapid and robust measure of perceived functioning.

Authors:  Peter Tyrer; Ula Nur; Mike Crawford; Saffron Karlsen; Claire McLean; Bharti Rao; Tony Johnson
Journal:  Int J Soc Psychiatry       Date:  2005-09

6.  Meta-analyses involving cross-over trials: methodological issues.

Authors:  Diana R Elbourne; Douglas G Altman; Julian P T Higgins; Francois Curtin; Helen V Worthington; Andy Vail
Journal:  Int J Epidemiol       Date:  2002-02       Impact factor: 7.196

7.  The estimation of intraclass correlation in the analysis of family data.

Authors:  A Donner; J J Koval
Journal:  Biometrics       Date:  1980-03       Impact factor: 2.571

Review 8.  Monitoring and care of young people at incipient risk of psychosis.

Authors:  A R Yung; P D McGorry; C A McFarlane; H J Jackson; G C Patton; A Rakkar
Journal:  Schizophr Bull       Date:  1996       Impact factor: 9.306

9.  Change in personality status in neurotic disorders.

Authors:  Helen Seivewright; Peter Tyrer; Tony Johnson
Journal:  Lancet       Date:  2002-06-29       Impact factor: 79.321

10.  Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms.

Authors:  Patrick D McGorry; Alison R Yung; Lisa J Phillips; Hok Pan Yuen; Shona Francey; Elizabeth M Cosgrave; Dominic Germano; Jenny Bravin; Tony McDonald; Alison Blair; Stephen Adlard; Henry Jackson
Journal:  Arch Gen Psychiatry       Date:  2002-10
View more
  1 in total

Review 1.  Diagnosis and treatment of schizotypal personality disorder: evidence from a systematic review.

Authors:  Sophie K Kirchner; Astrid Roeh; Jana Nolden; Alkomiet Hasan
Journal:  NPJ Schizophr       Date:  2018-10-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.